TheJakartaPost

Please Update your browser

Your browser is out of date, and may not be compatible with our website. A list of the most popular web browsers can be found below.
Just click on the icons to get to the download page.

Jakarta Post

Ebola, Zika push drugmakers to join effort to avert pandemics

James Paton (Bloomberg)
London
Thu, January 19, 2017

Share This Article

Change Size

Ebola, Zika push drugmakers to join effort to avert pandemics A mosquito bite is developing syimptoms (Bloomberg/File)

S

purred by the Ebola and Zika epidemics, GlaxoSmithKline Plc, Johnson & Johnson and Sanofi are among drugmakers backing an effort to develop new vaccines that could be deployed swiftly to contain outbreaks before they spark global emergencies.

Pharmaceutical companies are working with the Coalition for Epidemic Preparedness Innovations, which has raised $460 million from the governments of Germany, Japan and Norway, as well as the Bill & Melinda Gates Foundation and the Wellcome Trust, the group said on Wednesday.

Glaxo, the U.K.’s biggest drugmaker, is willing to commit a significant portion of the estimated $40 million to $50 million in annual costs to operate a proposed biopreparedness facility focused on vaccines, while giving the group access to its work, Chief Executive Officer Andrew Witty said in a telephone interview. New vaccines must advance to at least the second of three stages of clinical tests to provide a type of “insurance policy” against epidemics, Witty said.

“When you look at the different pandemic threats over the last 10 or 12 years, the global response has been challenged each time,” he said from Davos, Switzerland. “The goal would be to have more, let’s say, phase II completed vaccines ready against the risk of potential pathogens, so when one of those -- god forbid -- comes along, we’ll have much better readiness.”

(Read also: Government intensifies research on Zika virus)

‘Tragically Unprepared’

The global partnership aims to shorten the time it takes to develop vaccines to protect against viruses that suddenly emerge as public-health threats. The coalition, which now raised almost half the money needed for the first five years, will target the MERS, Lassa and Nipah viruses first, aiming for two vaccine candidates against each of those diseases. India, a co-founder of the group, also plans to commit funding.

Ebola and Zika showed that the world is “tragically unprepared” to detect and respond quickly to outbreaks, Bill Gates, co-chair of the Gates foundation, said in the statement. The most recent Ebola outbreak in West Africa led to more than 11,000 deaths and exposed holes in infectious disease response, with sick travelers reaching as far away as Texas.

Glaxo’s planned biopreparedness unit would be based in Rockville, Maryland, where the London-based company has already opened a new global vaccines research and development center. The facility would operate on a “no profit, no loss” basis and help reduce disruption in a potential crisis, Witty said.

The global coalition aims to help move promising vaccines through early development for diseases that may kindle severe epidemics. It will also help defend against unknown or new viruses, according to the statement.

{

Your Opinion Matters

Share your experiences, suggestions, and any issues you've encountered on The Jakarta Post. We're here to listen.

Enter at least 30 characters
0 / 30

Thank You

Thank you for sharing your thoughts. We appreciate your feedback.